To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects

NCT07371065 | Enrolling By Invitation Phase 1

• 1 other identifier: LY03021/CT-CHN-101
• Study Type: interventional
• Target: 98
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multicenter, randomized withdrawal, double-blind, parallel, placebo-controlled design clinical trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets to evaluate the long-term efficacy and safety in the treatment of Chinese patients with depression.

Conditions

Major Depressive Disorder

Outcome Measures

Primary Outcomes (1)

• Adverse Event

  Day 12

Secondary Outcomes (2)

• PK parameters: Cmax

  Day 12

• PK parameters: Tmax

  Day 12

Study Arms (2)

LY03021 group

EXPERIMENTAL

Orally only once

Drug: LY03021

Placebo

SHAM COMPARATOR

Orally only once

Drug: placebo

Interventions

LY03021 DRUG

Orally only once

LY03021 group

placebo DRUG

Orally only once

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Those who voluntarily participate in and sign the informed consent form after understanding the purpose, content, process and possible risks of the trial;
• Healthy male/female volunteers between 18 and 45 years of age, inclusive, at the time of signing the informed consent form;
• Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and body mass index (BMI) 18.5 kg/m2\~ 28.0 kg/m2 (including the boundary value) at screening;
• Be able to communicate well with the Investigator and comply with the lifestyle restrictions specified in the protocol and various requirements of the clinical trial (scheduled visits, laboratory tests and other trial procedures).

You may not qualify if:

• Known to have a history of allergy to any component of the Investigational product or similar drugs, or allergic constitution (previous allergy to two or more foods or drugs);
• The subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to a past or present respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry, dermatology and any other clinically significant disease or chronic disease; or any other disease that may interfere with the test results;
• Any surgical conditions or conditions that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a risk to the subjects participating in the trial, including a history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcers, gastrointestinal bleeding, etc.;
• Subjects with current or past mental disorders and brain dysfunction, or at risk of suicide according to Columbia-Suicide Severity Rating Scale (C-SSRS), or having a suicide risk at the discretion of the Investigator, , or with a history of self-mutilation;
• History of substance abuse or positive result in urine drug screening within 1 year prior to dosing;
• History of alcohol abuse (defined as more than 14 standard units of alcohol per week, 1 unit = 360 mL of beer or 45 mL of 40% spirits or 150 mL of wine) or positive breath test results within 1 year before dosing;
• Subjects who have a history of surgery within 3 months before dose administration, or have not recovered from surgery, or have an anticipated surgical planning during the trial;
• Those who have participated in other clinical trials within 3 months before dose administration (including drug and medical device clinical trials, the time is based upon the last visit);
• Blood donation or blood loss ≥ 400 mL within 3 months before dose administration, or blood donation or blood loss ≥ 200 mL within one month, or having a history of using blood products;
• Pregnant and lactating women; and those who refuse to take effective contraception measures (such as abstinence, intrauterine device or condom with intravaginal spermicide, etc.) during the study period and within 28 days after the end of the study, or have the plan to donate sperm or eggs;
• Abnormalities in vital signs, laboratory tests and 12-lead electrocardiogram (ECG) , and clinically significant as judged by the Investigator, for example:
• QTc \> 450 ms for males and \> 460 ms for females, Friericia's correction; Resting pulse rate \< 55 beats/min or \> 100 beats/min; systolic blood pressure \< 90 mmHg or ≥ 140 mmHg; diastolic blood pressure \< 60 mmHg or ≥ 90 mmHg;
• Use of the following medications or treatments prior to dosing:
• Use of any prescription medication within 28 days prior to dosing; Use of any over-the-counter medications, including health products, within 7 days prior to dosing;
• Hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), syphilis serum reaction (Trust) non-negative;

Sponsors & Collaborators

• Luye Pharma Group Ltd.: lead

Study Sites (1)

No. 604 Lingling Road, Shanghai

Shanghai, China

Location

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 5, 2025
• First Posted: January 27, 2026
• Study Start: October 28, 2025
• Primary Completion: April 30, 2026
• Study Completion: April 30, 2026
• Last Updated: January 27, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)